文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 临床医学 > 吉非替尼治疗晚期非小细胞肺癌的系统评价
侵权投诉

吉非替尼治疗晚期非小细胞肺癌的系统评价

Review Articles

Chin J Evid-based Med 2009, 9(2): 218-229

徐风华 郭荣荣 孙华燕

解放军总医院循证医学中心/制剂室(北京 100853)

摘要 目的 系统评价吉非替尼作为非小细胞肺癌二线治疗药物的疗效及不良反应。方法 电子检索MEDLINE(1991~2008.6)、Cochrane Library(2008年第4期)、CBMdisc(1978~2008.2)等数据库,对符合纳入标准的随机对照试验(RCT),采用RevMan 4.2软件进行Meta分析。对于国内无对照临床研究资料,采用同质合并分析。结果 共纳入8个RCT和36个无对照的临床研究。RCT结果表明,吉非替尼250 mg组与 500 mg组相比,症状改善、有效率、生存期和生存率无明显差异,250 mg组不良反应显著低于500 mg组。与安慰剂比较的RCT结果表明,吉非替尼作为NSCLC的联合一线治疗、三线治疗方案均不能提高缓解率、延长生存期或提高生存率;作为二线治疗方案时,尽管比安慰剂有较高的缓解率和略长的1年生存率[OR=1.40,95%CI(1.10,1.78),P<0.01],但不能延长患者生存期。吉非替尼的不良反应发生率明显高于安慰剂。与多烯紫杉醇比较的RCT结果表明,吉非替尼作为NSCLC二线治疗可以取得与多烯紫杉醇相似的疗效[OR=1.18,95%CI(0.84,1.67),P=0.35],且提高生存质量[OR=1.58,95%CI(1.33,1.89),P<0.000 01]。36篇国内无对照病例研究纳入病例1 680例,其中1篇为吉非替尼在中国注册的临床试验,6篇为记名供药计划(expanded access program,EAP)的研究结果。临床研究的总体结果表明,治疗完全缓解率2.2%,部分缓解率25.8%,疾病稳定率40.0%,疾病进展率32.0%。平均中位生存期8.9月;平均疾病进展时间5.2月,1年生存率44.2%。EAP研究的平均中位生存期(6.9月)低于注册临床研究(10.0月)和总结果;平均疾病进展时间注册临床研究(3.2月)和EAP研究(4.4月)小于总结果;注册临床研究、EPA研究和全部研究的缓解率及1年生存率相似。上述无对照的临床试验结果很难说明吉非替尼治疗NSCLC中国患者有确切的疗效。结论 吉非替尼不适于晚期NSCLC的联合一线治疗或三线治疗,二线治疗的临床获益不明确。尚无充分证据显示在治疗晚期NSCLC时中国人对吉非替尼更为敏感,吉非替尼在中国作为NSCLC二线治疗方案的有效性仍缺乏有力的临床证据。

关键词 晚期非小细胞肺癌;吉非替尼;治疗;Meta分析

Systemic Evaluation of Gefitinib in the Treatment of Non-small-cell Lung Cancer

XU Feng-hua, GUO Rong-rong, SUN Hua-yan

Department of Pharmaceutical Care, PLA General Hospital, Beijing 100853, China

Abstract Objective To evaluate the efficacy of Gefitinib for patients with non-small-cell lung cancer (NSCLC). Methods We searched several databases, including MEDLINE (1991 to June 2008), The Cochrane Library (Issue 4, 2008) and CBMDisc (1978 to Feb. 2008). Randomized controlled trials (RCTs) were included in the meta-analyses, which were done using The Cochrane Collaboration’s RevMan 4.2 software. We also included retrospective case reports published in Chinese journals. Results Eight RCTs and 36 uncontrolled case reports were analyzed. The results of the RCTs showed that 250 mg/d Gefitinib had similar efficacy to 500 mg/d, but the side effect was significantly less for the lower dose. When used as a combined first-line treatment or a third-line treatment, Gefitinib was not superior to placebo on response rate, survival rate and life span. When used as second-line treatment, it did not prolong median survival, though it gave a higher response rate than placebo. Gefitinib caused many more side effects than placebo. Gefitinib exhibited similar efficacy to docetaxel in objective response rate [OR 1.18, 95%CI (0.84, 1.67), P=0.35], but was better for symptom and quality-of-life improvement [OR 1.58, 95%CI (1.33, 1.89), P<0.00001]. The overall uncontrolled clinical studies showed the following results: complete response rate was 2.2%, partial response rate was 25.8%, disease stable rate was 40.0% and progressive disease rate was 32.0%. The average median survival time was 8.9 months; the average time to progressive disease was 5.2 months, and the 1-year survival rate was 44.2%. The average median survival from EAP studies (6.9 months) was shorter than that for all the studies as well as the registered clinical trials (10.0 months). The average periods to progressive disease for registered clinical trials (3.2 months) and EAP studies (4.4 months) were somewhat shorter than that found for all studies combined, though response rate and 1-year survival rate were similar. Since there was no

作者简介:徐风华,女,研究员,硕士研究生导师,Email: xufh@yahoo.com

CJEBM 218

© 2009 Editorial Board of Chin J Evid-based Med

doc.guandang.net

第1页

你可能喜欢

  • 小细胞肺癌NCCN指南
  • 肿瘤靶向治疗药物
  • 肿瘤靶向药物
  • 吉西他滨
  • 肺癌药物
  • 小细胞肺癌诊断
  • 肺癌治疗指南

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email